Management of Epstein-Barr Virus Positive Splenomegaly with Areas of Infarction
Diagnosis and Assessment
- CT scan with intravenous contrast is the gold standard for diagnosing splenic infarction, with sensitivity and specificity of 90-95%, showing peripheral low-density, wedge-shaped areas 1
- MRI offers similar diagnostic accuracy to CT for splenic infarction, while ultrasonography is less sensitive 1
- EBV infection should be confirmed through serological testing (EBV IgM, IgG) and/or PCR testing of blood samples 2
- Monitor for signs of complications including persistent fever, recurrent bacteremia, or other signs of sepsis which may indicate progression to splenic abscess 1
Initial Management
- Monitor EBV viral load by quantitative PCR to assess disease activity and response to treatment 2
Monitoring for Complications
- Regular clinical assessment for signs of splenic rupture or hemorrhage, which is a rare but serious complication 1
- Serial imaging (ultrasound or CT) to monitor the evolution of splenic infarcts and splenomegaly 1
- Watch for development of pseudocyst formation as a potential complication 1
- Monitor for signs of secondary bacterial infection or abscess formation 1
Indications for Surgical Intervention
- Splenectomy is indicated for development of splenic abscess 1
- Surgical intervention is necessary for splenic rupture with hemorrhagic shock or failed non-operative management with continued hemodynamic instability 1, 3
- Consider intervention for persistent symptoms and complications such as hemorrhage, splenic abscesses, or pseudocyst formation 3
Special Considerations
- In patients with underlying hematological conditions, cytoreductive therapy for the primary disease can lead to successful regression of splenic infarction without surgical intervention 3
- For patients with post-transplant EBV infections, reduction of immunosuppression should be considered when possible 4
- In transplant patients with high EBV viral loads, rituximab (375 mg/m²) may be considered as pre-emptive therapy to prevent progression to post-transplant lymphoproliferative disorder (PTLD) 4